In the English literature, portal vein obstruction was first reported in 1868 by Balfour and Stewart, who described a patient presenting with an enlarged spleen, ascites, and variceal dilatation.
The vast majority of cases are due to primary thrombosis of the portal vein; most of the remaining cases are caused by a malignant obstruction. See the images below.
View Image
Portal vein thrombosis with cavernous transformation. The long arrow indicates the splenic vein at the junction with the superior mesenteric vein just....
View Image
Hepatocellular carcinoma with portal vein thrombosis. The short arrow indicates the tumor thrombus with an abrupt cut off of the portal vein. The long....
The portal vein forms at the junction of the splenic vein and the superior mesenteric vein behind the pancreatic head, and it can become thrombosed or obstructed at any point along its course. In cirrhosis and hepatic malignancies, the thromboses usually begin intrahepatically and spread to the extrahepatic portal vein. In most other etiologies, the thromboses usually start at the site of the origin of the portal vein. Occasionally, thrombosis of the splenic vein propagates to the portal vein, most often resulting from an adjacent inflammatory process such as chronic pancreatitis.
Inherited and acquired disorders of the coagulation pathway are frequent causes of portal vein thrombosis. Inherited disorders include factor V Leiden deficiency and mutations in the prothrombin gene G20210A as well as deficiencies of various intrinsic anticoagulation factors, such as protein C and protein S, and activated protein C resistance. Acquired disorders include antithrombin III deficiency resulting from malnutrition, sepsis, disseminated intravascular coagulation, inflammatory bowel disease, liver disease, or estrogen use. See the image below.
View Image
Coagulation disorders in portal vein thrombosis.
Stasis is another major category for portal vein thrombosis. The global resistance to hepatic blood flow produced by cirrhosis is a common cause. Sclerotherapy for esophageal varices has been postulated as a possible mechanism though not proven thus far. The portal vein or its tributaries can be obstructed by adjacent tumor compression or invasion. Infectious and inflammatory processes may also lead to venous thrombosis.
Portal vein obstruction does not affect the liver function unless the patient has an underlying liver disease such as cirrhosis.[1] This is partially due to a rapid arterial buffer response, with compensatory increased flow of the hepatic artery, maintaining the total hepatic blood flow. Formation of collaterals occurs rather rapidly as well, and they have been described as early as 12 days after an acute thrombosis, though the average time to formation is approximately 5 weeks.
The development of collateral circulation, with its attendant risk of variceal hemorrhage, is responsible for most of the complications and is the most common manifestation of portal vein obstruction. The other sequelae of the subsequent portal hypertension, such as ascites, are less frequent. Rarely, the thrombosis extends from the portal vein to the mesenteric arcades, leading to bowel ischemia and infarction.
In children and neonates, the most common etiology is intra-abdominal infection, accounting for 50% of all cases in this age group. Neonatal sepsis with umbilical catheter placement has been reported to be the cause of portal vein thrombosis in 10-26% of cases.
Appendicitis is a commonly reported risk factor in children with portal vein thrombosis.
Congenital anomalies of the portal venous system, often associated with cardiovascular anomalies (eg, ventricular and atrial septal defects, deformed inferior vena cava) and biliary tract abnormalities, have been reported in 20% of children with portal vein obstruction and thrombosis.
Adults
In adults, cirrhosis is the major etiology, accounting for 24-32% of cases of portal vein thrombosis.
Neoplasms are another major cause, accounting for 21-24% of cases of portal vein obstruction, with hepatocellular carcinoma and pancreatic carcinoma causing most of these cases.[6] These tumors can cause compression or direct invasion of the portal vein or lead to thrombosis by inducing a hypercoagulable state.[7] Local ablative therapies for hepatocellular carcinoma or metastatic disease have been linked to its development.
Although less common than in children, infections (predominantly intra-abdominal) still play an important role, with a particular association with Bacteroides fragilis bacteremia.
Myeloproliferative disorders and inherited or acquired hypercoagulable disorders account for 10-12% of cases in adults.
Approximately 8-15% of cases have been reported to be idiopathic in the recent literature. For other less common etiologies, such as abdominal trauma, surgery, and inflammatory bowel disease, see the image below.
Portal vein obstruction is a relatively rare condition with an overall incidence of 0.05-0.5% in autopsy studies. The incidence varies, depending on the group of patients studied (eg, general population vs patients with cirrhosis) and the method used to diagnose portal vein obstruction (eg, autopsy studies, angiography studies, noninvasive radiological screening).
The incidence of portal vein obstruction in people with cirrhosis has been reported to vary from 5-18%. However, these were patients referred for transplantation and were at an advanced stage of liver disease. No large autopsy studies are available. Extrahepatic portal vein obstruction is estimated to be responsible for 5-10% of all cases of portal hypertension.
International statistics
In Japan, the frequency of portal vein obstruction in autopsy studies was reported to be 0.05%. In an angiography surveillance study of patients with cirrhosis, the incidence was 0.5%, which is much lower than the reported incidence in the Western literature.
In India, extrahepatic portal vein obstruction is reported more frequently; in one study, the incidence even exceeded reported cases of cirrhosis. Of all cases of portal hypertension in developing countries, 40% are attributed to portal vein obstruction, presumably secondary to an increased incidence of pylephlebitis associated with abdominal infections.
Sex- and age-related demographics
No sex differences have been reported overall, except for a slight male predominance in patients whose obstruction is secondary to cirrhosis.
The distribution of the age at presentation of portal vein thrombosis reflects the demographics of the underlying disease process. Primary portal vein thrombosis from coagulopathies occurs with equal frequency in adults and children.[2] The frequency of portal vein obstruction from tumor compression or invasion is greater in adults.
The overall prognosis is good, with 75% of patients alive after 10 years and an overall mortality rate of less than 10%.
In the presence of cirrhosis and malignancy, the prognosis is understandably worse and is dependent upon the underlying condition.
Mortality/Morbidity
In the absence of cirrhosis, the 2 year bleeding risk from esophageal varices is reported to be 0.25% and of those that bleed the mortality rate is approximately 5%. Those with cirrhosis and varices have a 20-30% 2 year bleeding risk with a mortality rate of 30-70%. This difference is primarily a consequence of the normal hepatic function in the noncirrhotic patient. The variceal size is the major predictive factor for bleeding.
In adults with portal vein thrombosis, the 10-year survival rate has been reported to be 38-60%, with most of the deaths occurring secondary to the underlying disease (eg, cirrhosis, malignancy).
In children with portal vein thrombosis, the prognosis is much better overall, with a 10-year survival rate greater than 70%, which is attributable to the low incidence of underlying malignancy and cirrhosis.
Complications
Complications of portal vein obstruction include the following:
Variceal hemorrhage
Ascites
Mesenteric infarction
Hypersplenism
Hepatic encephalopathy (rare)
Worsening hepatic function in patients with cirrhosis
In the acute phase, the presentation of portal vein obstruction is relatively uncommon and easily missed because the patient may be asymptomatic. Symptoms most often begin in the chronic or subacute stage. Schistosomiasis can cause presinusoidal portal obstruction by blocking the intrahepatic portal venules with parasite eggs. It does not cause extrahepatic portal vein obstruction, though the clinical manifestations are often similar.
Acute
Patients can present emergently with sudden onset of right upper quadrant pain, nausea, and/or fever. Alternatively, the symptoms of the primary infectious and inflammatory condition that led to the portal vein obstruction predominate (eg, right lower quadrant pain in appendicitis).
Progressive ascites, intestinal ischemia resulting from the propagation of the thrombus, or intestinal suffusion secondary to acute portal hypertension can also be the presenting manifestations. Occasionally, variceal bleeding can occur acutely with the development of portal vein thrombosis, particularly in the setting of preexisting varices with cirrhosis.
Spontaneous resolution of acute/recent thrombosis undoubtedly occurs and symptoms abate. In other patients, the acute symptoms often subside as collaterals develop, and the diagnosis may be missed. These patients then present at a later stage with manifestations of portal hypertension.
Chronic
These groups of patients most often present with complications related to portal hypertension. In 90% of cases, variceal bleeding is the presenting complaint. On average, this occurs 4 years after the thrombotic event and has been described as long as 12 years later. Ascites is less frequent, and hepatic encephalopathy is rare in the absence of preexisting cirrhosis.[3]
The specific etiology of the portal vein obstruction not only influences the initial clinical presentation but also the time course and prognosis.
In the presence of cirrhosis with underlying hepatic insufficiency, sudden worsening of hepatic function, development of hepatic encephalopathy, and the development of ascites are all more frequent, leading to worse outcomes.
With intra-abdominal malignancies, bleeding is less commonly the first manifestation because many of these patients do not survive long enough to develop the sequelae of portal hypertension. These patients most often present with sudden ascites, anorexia, right upper quadrant or epigastric pain, and weight loss. Portal vein obstruction may also be discovered incidentally on imaging studies obtained for pain or ascites.
Rarely, patients with portal vein obstruction present with a fever of unknown origin.
Splenomegaly is found in 75-100% of patients, most presenting in the chronic stage. Mild hepatomegaly is often present, as is right upper quadrant epigastric tenderness, especially in the acute setting.
Ascites is found infrequently. Stigmata of chronic liver disease, such as spider angiomata or palmar erythema, are usually found in the presence of an underlying liver disease.
The presence of caput medusae indicates posthepatic or intrahepatic portal hypertension because it forms by recanalization of the umbilical vein, which connects with the left hepatic branch of the portal vein.[4] It should not be observed in isolated extrahepatic portal vein obstruction because the obstruction is below the origin of the umbilical vein.
In children, growth retardation may be present.[5]
Abnormalities of the extrahepatic biliary tree may occur in 80% of cases due to compression by choledochal or periportal varices or from ischemic stricturing. These findings manifest by jaundice, cholangitis, hemobilia, cholecystitis, or a hilar mass that can be mistaken for a cholangiocarcinoma.
Liver function test results are only mildly elevated in the absence of an underlying cirrhosis or massive hepatic malignancy.
Inherited coagulation disorders, such as activated protein C resistance, are listed in the image below. Tests for these disorders should be ordered in any case of portal vein thrombosis in which the diagnosis is unclear.
View Image
Coagulation disorders in portal vein thrombosis.
In the presence of an underlying hepatic insufficiency, levels may be low, presumably secondary to decreased production in the liver. Caution is therefore needed in making the diagnosis of an inherited thrombophilic disorder in this scenario.
Some authors suggest checking for an inherited coagulation disorder even when a local factor for portal vein thrombosis is obvious and, conversely, also checking for local factors even in the presence of inherited coagulation disorders because more than one risk factor may be present in a single patient.
Ultrasonography is the first-line diagnostic modality because of its accuracy, affordability, and noninvasiveness. Note the following:
The thrombus is observed as an echogenic lesion within the portal vein, though a recently formed thrombus may be anechoic (ie, not observable on standard grey-scale ultrasound).
The addition of color Doppler imaging is especially helpful in the detection of portal vein flow and the diagnosis of portal vein obstruction.
The sensitivity is around 70-90%, with a specificity of 99%. With Doppler, the false-positive rate is 9% in patients with cirrhosis because of sluggish or turbulent portal vein flow.
Major limitations are obesity and nonvisualization secondary to bowel gas.[8]
The presence of pulsatile, arterial flow in the thrombus correlates with a malignant, not bland, thrombus.
Endoscopic ultrasonography (EUS)
Although not a common diagnostic modality, EUS has recently been found to be 81% sensitive and 93% specific in patients with portal vein thrombosis as compared to patients with thrombus confirmed by contrast-enhanced CT scan or surgery.
MRI and magnetic resonance angiography (MRA)
MRI/MRA is the next step if further portal venous information is needed. MRI is helpful if hepatic parenchymal detail is required (in hepatic malignancies), and, unlike CT scan, MRI can also quantitate portal and hepatic vessel flow, which is required in the planning of interventions, such as shunt surgery, transjugular intrahepatic portosystemic shunt (TIPS), or liver transplantation. Note the following:
Acute clot (<5 wk) appears hyperintense on both T1- and T2-weighted images, whereas older clots appear hyperintense only on T2-weighted images. Tumor thrombi can be differentiated from bland thrombi because they appear more hyperintense on T2-weighted images and enhance with gadolinium.
The overall sensitivity, specificity, and accuracy of the MRA are 100%, 98%, and 99%, respectively. There is a high sensitivity for the detection of submucosal, serosal, paraesophageal collaterals.
CT scanning
Contrast-enhanced CT scanning shows a thrombus as a nonenhanced intraluminal-filling defect. (See the images below.) This imaging modality has the advantage over ultrasonography in displaying varices (sensitivity, 65-85%) and parenchymal hepatic abnormalities.
The combination of CT scan and Doppler ultrasonography is common in the evaluation of portal vein obstruction.
View Image
Portal vein thrombosis with cavernous transformation. The long arrow indicates the splenic vein at the junction with the superior mesenteric vein just....
View Image
Hepatocellular carcinoma with portal vein thrombosis. The short arrow indicates the tumor thrombus with an abrupt cut off of the portal vein. The long....
Angiography
Angiography is not usually required to confirm the diagnosis of portal vein thrombosis in the presence of CT scan or MRI. Angiography's major value lies in preoperative planning before shunt surgery or liver transplantation; however, it is not a prerequisite, and many transplant centers use MRI/MRA for this purpose.
Even angiography can provide false-positive results in portal hypertension in the presence of extensive portosystemic collaterals in which the mesenteric flow is directed away from a patent portal vein.
Usually, no specific alterations are observed on the histologic examination of the liver. In rats, apoptosis has been described in the underperfused portion, with increased mitotic activity in the remaining well-perfused liver.
The primary goals are to alleviate acute bleeding and to prevent further bleeding. In the acute setting, these goals are best accomplished with variceal banding or sclerotherapy, often requiring several sessions to obliterate the varices. This has a success rate of 95% for controlling an acute bleed.
Octreotide infusion has also been used in acute bleeding, with control of the acute bleed in 85% of patients. The rate of recurrent bleeding with this approach is 16-28%.
In the setting of portal vein obstruction, the role of propranolol to prevent rebleeding has not been studied, though it is used routinely.
After endoscopic therapy of bleeding varices, propranolol is instituted with a goal of reducing the heart rate by 25% below baseline.
Treatment of underlying etiology
Anticoagulation in patients with acute/recent portal vein thrombosis, studied only retrospectively, has been shown to recanalize the thrombosed vessel in more than 80% of cases. This is essential to prevent the advancement of thrombosis or rethrombosis in patients with inherited coagulation disorders in which lifelong anticoagulation therapy is recommended once variceal control has been achieved. Anticoagulation therapy has also been recommended after shunt surgery to prevent rethrombosis. In one study in which 84 of 136 nonmalignant, noncirrhotic patients with portal vein thrombosis were anticoagulated with similar bleeding risks but less risk for thrombotic propagation. Debate remains regarding the risk-to-benefit ratio of anticoagulation in chronic portal vein thrombosis and should be decided on a case-by-case approach at this time.
Thrombolysis
Thrombolysis is recommended in acute portal vein thrombosis through the transhepatic route, which avoids the need for systemic thrombolysis.
Tissue-type plasminogen activator (tPA) has been used for this purpose, followed by prolonged anticoagulation therapy with Coumadin for at least 3 months (indefinitely in patients with inherited coagulation disorders).
In the setting of acute portal vein thrombosis with symptoms, shunt surgery with subsequent anticoagulation therapy is an alternative.
In a study consisting of 65 children (median age, 12.5 y) with extrahepatic portal vein obstruction, a stepwise treatment protocol involving medical, endoscopic, and surgical approaches resulted in good outcomes.[9] The protocol took into consideration the severity of the portal hypertension and the feasibility of mesoportal bypass. The children underwent surveillance endoscopies: Those with large varices received nonselective beta blockers (NSBBs) or underwent variceal obliteration (EVO). For patients with disease refractory to NSBBs and EVO, mesoportal bypass was the first-line treatment, and transjugular intrahepatic portosystemic shunt surgery was second-line therapy. There was a 93% survival with bleeding control, and 82% had a patent conduit.[9]
Transfer
For variceal bleeding refractory to endoscopic therapy or recurrent bleeding after endoscopic therapy, transfer to a center experienced in TIPS placement or shunt surgery is recommended.
Transfer to a liver transplantation center is recommended for patients with hepatic dysfunction related to cirrhosis in the setting of portal vein thrombosis.
Outpatient monitoring
Patients that had endoscopic ligation of varices should have repeat endoscopies every 2-4 weeks with the goal of complete eradication of varies.
After TIPS placement, repeat ultrasonography is recommended (initially, 4 wk after placement, then every 3 mo) to check patency of the stent. If significant occlusion is discovered, revision can be performed, usually in the outpatient setting.
In portal vein obstruction, the place for shunt surgery in the treatment of variceal bleeding is debated. Some authors recommend endoscopic treatment and propranolol as first-line treatment to prevent recurrent bleeding. Others recommend shunt surgery after the first variceal bleed to prevent further rebleeding.
In general, shunt surgery should only be attempted when endoscopic treatment fails.
A distal splenorenal shunt is usually the preferred surgical shunt. For patients in whom the splenic vein is also thrombosed and surgery is undertaken, splenectomy and other shunt procedures (eg, the Sugiura procedure) have been performed. A more recent salvage operation showing success is the right and left mesogonadal shunt. In patients who are critically ill, esophagogastrectomies have been used as a last resort.
In the presence of cirrhosis, the operative mortality rate has been reported to be 18%. In the absence of cirrhosis, operative mortality is approximately 2%. The postoperative complication rate is approximately 30%.
The presence of liver nodules has been reported following portal systemic shunt surgery in animal models and in humans with liver cirrhosis. In a small retrospective study of 45 children without liver disease, Guerin et al examined the incidence of liver nodules following surgical intervention for extrahepatic portal vein obstruction.[10] Using ultrasonography, the investigators noted 7 (15%) of the children had liver nodules (median 80 months' follow-up), all of which occurred following portal systemic shunt surgery and 5 of which demonstrated either liver cell adenomas (2 nodules) or focal nodular hyperplasias (3 nodules).[10] Guerin et al recommended keeping in mind the possible presence of liver nodules during follow-up of children post portal systemic shunt surgery for extrahepatic portal vein obstruction.[10]
TIPS
Previously considered a relative contraindication in portal vein thrombosis, TIPS has been successfully used in this condition. Stent placement requires an aspiration thrombectomy through a sheath with subsequent angioplasty of the tract and stent placement. Some centers have obtained good results by performing an embolectomy and then using local thrombolytic therapy through the TIPS after deployment.
In portal vein obstruction, TIPS is indicated in uncontrollable variceal bleeding in a patient with cirrhosis, usually as a bridge to transplant. The choice of TIPS over shunt surgery depends upon the expertise of the center in these techniques and the distance from skilled health care because TIPS is more likely to occlude and require revision. However, TIPS has the advantage of being less invasive than shunt surgery.
In the setting of portal vein obstruction and cirrhosis, TIPS has a success rate of 69% in controlling variceal bleeding and a complication rate of 22%, including a mortality rate of 11% in one series.
Liver transplantation
In patients referred for orthotopic liver transplantation (OLT), portal vein thrombosis complicates 5-15% of cases.
Although traditionally viewed as a relative contraindication to OLT, recent innovative surgical techniques (eg, thrombectomy, venous jump grafts, use of portal vein tributaries) have resulted in improved results post-OLT in end-stage liver disease with portal vein thrombosis.
In patients with associated portal vein thrombosis, the 5- and 10-year survival rates after OLT are approximately 63% and 53%, respectively, whereas, in patients without thrombosis, the 5- and 10-year survival rates after OLT are 67% and 59%, respectively. Moreover, a higher incidence (5%) of primary nonfunction, renal failure, and recurrent portal vein thrombosis exists.
In young, otherwise healthy patients with extension of thrombus to the splenic and mesenteric venous systems, eliminating surgical shunt options, should be considered for multivisceral transplantation.
Gastroenterologists and hepatologists: Seek a consultation for management of acute variceal bleeding and to coordinate further management.
Interventional radiologists: Seek a consultation for consideration of TIPS, especially if recurrent variceal bleeding exists in a transplant candidate.
General surgeons and transplant surgeons: Seek a consultation for consideration of shunt surgery and to assess transplant suitability in patients with underlying cirrhosis.
Clinical Context:
Nonselective beta-blocker that reduces the risk of primary and recurrent variceal bleeding by decreasing the portal pressure. Indicated for primary and secondary prophylaxis of variceal bleeding.
Inhibit chronotropic, inotropic, and vasodilatory responses to beta-adrenergic stimulation. Doses to treat variceal bleeding vary. Long-term administration of oral propranolol has been used in doses of 20-360 mg/d. Randomized trials have used 20-120 mg/d. Gradually increase doses, with a goal of reducing the resting heart rate by 25%. Treatment efficacy may also be measured by reducing the hepatoportal venous gradient (HPVG) to less than 12.
Clinical Context:
Reduces portal flow, thereby reducing portal hypertension. Mechanism of action in this setting is not fully understood. Used in acute variceal bleeding and for recurrent bleeding after endoscopic therapy.
Have various effects on GI secretion, glandular secretion (eg, growth hormone, insulin, glucagon), and smooth muscle contraction. Inhibit splanchnic blood flow.
Used in the treatment and prophylaxis of thromboembolic disorders. Include direct anticoagulants (eg, heparins, low molecular weight heparins, heparinoids) and indirect anticoagulants (eg, warfarin).
Clinical Context:
Recombinant thrombolytic agent also known as tPA. Plasminogen activation results in the formation of plasmin, which is the enzyme responsible for clot dissolution.
Fibrinolysis is the mechanism of clot dissolution. It is mediated by plasminogen, which circulates in the plasma in an inactive form; conversion to its active form, plasmin, occurs when plasminogen binds to fibrin in the presence of a plasminogen activator.
When was portal vein obstruction first reported?What is the pathophysiology of portal vein obstruction?What causes portal vein obstruction?What is stasis in portal vein obstruction?How does portal vein obstruction affect liver function and what are the complications?What causes portal vein obstruction in children?What causes portal vein obstruction in adults?What is the incidence of portal vein obstruction in the US?What is the international incidence of portal vein obstruction?What are the demographics of portal vein obstruction?What are the complications of portal vein obstruction?What is the prognosis of portal vein obstruction?What are the mortality and morbidity of portal vein obstruction?How is the presentation of portal vein obstruction characterized?What is the patient’s clinical history in chronic portal vein obstruction?What are the physical findings in portal vein obstruction?What are the diagnostic considerations in portal vein obstruction?What are the differential diagnoses for Portal Vein Obstruction?Which lab studies are indicated in the workup of portal vein obstruction?What is the role of ultrasonography in the workup of portal vein obstruction?What is the role of endoscopic ultrasonography (EUS) in the workup of portal vein obstruction?What is the role of MRI/MRA in the workup of portal vein obstruction?What is the role of CT scanning in the workup of portal vein obstruction?What is the role of angiography in the workup of portal vein obstruction?What are the histologic findings in portal vein obstruction?How is acute bleeding controlled in patients with portal vein obstruction?What is the role of anticoagulation in portal vein obstruction?What is the role of thrombolysis in the treatment of portal vein obstruction?When is transfer indicated in the treatment of portal vein obstruction?What follow-up care is indicated for patients with portal vein obstruction?What is the role of shunt surgery in the treatment of portal vein obstruction?What is the role of transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of portal vein obstruction?How is portal vein obstruction associated with orthotopic liver transplantation (OLT) treated surgically?Which specialist consultations are indicated in the management of portal vein obstruction?What are the goals of drug treatment for portal vein obstruction?Which medications in the drug class Thrombolytic agents are used in the treatment of Portal Vein Obstruction?Which medications in the drug class Anticoagulants are used in the treatment of Portal Vein Obstruction?Which medications in the drug class Somatostatin analogs are used in the treatment of Portal Vein Obstruction?Which medications in the drug class Beta-adrenergic blocking agents are used in the treatment of Portal Vein Obstruction?
Adnan Said, MD, MSPH, Assistant Professor, Department of Medicine, Section of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health at Madison; Consulting Staff, Department of Medicine, William S Middleton Memorial Veterans Hospital
Disclosure: Nothing to disclose.
Specialty Editors
Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Noel Williams, MD, FRCPC, FACP, MACG, Professor Emeritus, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Professor, Department of Internal Medicine, Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
Disclosure: Nothing to disclose.
Chief Editor
BS Anand, MD, Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine
Disclosure: Nothing to disclose.
Additional Contributors
Ann Ouyang, MBBS, Professor, Department of Internal Medicine, Pennsylvania State University College of Medicine; Attending Physician, Division of Gastroenterology and Hepatology, Milton S Hershey Medical Center
Disclosure: Nothing to disclose.
Acknowledgements
Mark Reichelderfer, MD
Disclosure: Nothing to disclose.
Andrew Taylor, MD Professor, Department of Radiology, University of Wisconsin Hospitals and Clinics
Disclosure: Nothing to disclose.
Jennifer T Wells, MD Fellow, Department of Gastroenterology and Hepatology, University of Wisconsin Hospitals and Clinics, Madison
Jennifer T Wells, MD is a member of the following medical societies: American Medical Association and Phi Beta Kappa
Portal vein thrombosis with cavernous transformation. The long arrow indicates the splenic vein at the junction with the superior mesenteric vein just below the site of thrombosis. The short arrow points to a serpiginous mass consistent with periportal collaterals, the so-called cavernous transformation of the portal vein.
Hepatocellular carcinoma with portal vein thrombosis. The short arrow indicates the tumor thrombus with an abrupt cut off of the portal vein. The long arrow points to a compensatory, prominent left hepatic arterial branch.
Coagulation disorders in portal vein thrombosis.
The etiology of portal vein obstruction.
Coagulation disorders in portal vein thrombosis.
Portal vein thrombosis with cavernous transformation. The long arrow indicates the splenic vein at the junction with the superior mesenteric vein just below the site of thrombosis. The short arrow points to a serpiginous mass consistent with periportal collaterals, the so-called cavernous transformation of the portal vein.
Hepatocellular carcinoma with portal vein thrombosis. The short arrow indicates the tumor thrombus with an abrupt cut off of the portal vein. The long arrow points to a compensatory, prominent left hepatic arterial branch.
The etiology of portal vein obstruction.
Coagulation disorders in portal vein thrombosis.
Portal vein thrombosis with cavernous transformation. The long arrow indicates the splenic vein at the junction with the superior mesenteric vein just below the site of thrombosis. The short arrow points to a serpiginous mass consistent with periportal collaterals, the so-called cavernous transformation of the portal vein.
Hepatocellular carcinoma with portal vein thrombosis. The short arrow indicates the tumor thrombus with an abrupt cut off of the portal vein. The long arrow points to a compensatory, prominent left hepatic arterial branch.
){kind=link}
){kind=link}
){kind=link}
){kind=link}